# Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

> **NCT06375473** · — · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 3000 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan liposome II combination therapy regimen

## Key facts

- **NCT ID:** NCT06375473
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2027-04-19
- **Final completion:** 2027-04-19
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375473, "Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06375473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*